---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Pharmacokinetics"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Pharmacokinetics. Topics: Fc engineering for half-life extension, Phase 1 study design for pharmacokinetic assessment, Elimination half-life of approximately 60 days, Dose proportionality and accumulation in phase 1, and 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Fc engineering for half-life extension

> “Claseprubart is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic”
> “profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “YTE, 3 amino acid substitutions at positions 249, 251 and 253 in the IgG4 heavy chain constant region (M249Y/S251T/T253E)”

Source: [Gokhale et al. (2024)](https://investor.dianthustx.com/static-files/385658f0-0e93-4df3-8b31-a1c0077c9024)

<a id="topic-2.1.2.6.3-2"></a>

### Phase 1 study design for pharmacokinetic assessment

> “We evaluated DNTH103 in a first-in-human Phase 1 single ascending dose”
> “clinical trial in New Zealand to explore the safety, tolerability, PK, and pharmacodynamics”
> “We reported data from 60 healthy volunteers that have been dosed across eight cohorts, including six SAD cohorts: 1mg/kg intravenous”
> “10mg/kg I.V., 30mg/kg I.V., 50mg/kg I.V., 300mg S.C. and 600mg S.C.; and two MAD cohorts: 300mg S.C. and 600mg. S.C.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-2.1.2.6.3-3"></a>

### Elimination half-life of approximately 60 days

> “Additionally, based on data from this clinical trial, DNTH103 has a half-life of approximately 60 days.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

> “The top-line data confirmed its approximately 60-day half-life and highly potent classical pathway inhibition with Q2W S.C. dosing of 300mg/2mL surpassing the serum concentration required to surpass 90% classical pathway inhibition in a hemolytic assay estimated to be 87ug/mL”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “Highly potent, ~8-week half-life, Classical Pathway (CP) inhibitor targeting active C1s”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.6.3-4"></a>

### Dose proportionality and accumulation in phase 1

> “I.V. SAD: Linear PK with Exposure Proportional Across Doses S.C. MAD: Strong Accumulation with Q2W Dosing PK/PD: Analysis Demonstrates IC90 of 87 µg/mL Data comprised of 60 HVs from 8 cohorts”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="topic-2.1.2.6.3-5"></a>

### Simulated steady-state exposure relative to the IC90

> “With these data, we conducted a PK simulation that demonstrates the steady state serum concentration of DNTH103, when dosed 300mg S.C. Q2W following an initial I.V. loading dose, exceeds the serum concentration required to surpass 90% classical pathway inhibition in a hemolytic assay”
> “estimated to be 87ug/mL. We believe, based on published scientific literature related to other complement therapies, that the IC90 will be sufficient to achieve clinical activity in patients with gMG, CIDP, and MMN.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

> “Simulation using data from 60 healthy volunteers dosed across multiple cohorts demonstrates potent inhibition with infrequent S.C. dosing IC90 – 87 µg/mL Day 0: 15mg/kg I.V. Starting Day 7: 300mg S.C. Q2W Dosing Modeled”
> “300mg and 600mg S.C. Q2W dosing surpasses IC90 (87 µg/mL) and IC95 (149 µg/mL), respectively”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

<a id="topic-2.1.2.6.3-6"></a>

### Observed steady-state concentration with 300 mg every 2 weeks: phase 2

> “PK of ~65 μg/mL at week 4 after only two 600mg/4mL doses is substantially lower than steady state seen with 300mg/2mL dosing of ~100-120 μg/mL”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
